The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Health experts have slammed the FDA as 'corrupt' and 'in bed with Big Pharma' after its former drug chief Dr Patrizia ...
On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes may be less welcome. Here's what to expect.
The industry wants the ability to make bolder health claims and to get the government and private insurers to pay for its products — as they do FDA-approved drugs.
Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
The affected products were primarily distributed to long-term care facilities and were not available for retail sale ...
Those rehired by the Trump administration include at least 10 FDA staffers responsible for reviewing the safety of new food ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback